

# Harvey J Mamon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5296487/publications.pdf>

Version: 2024-02-01

75  
papers

3,624  
citations

168829

31  
h-index

150775

59  
g-index

75  
all docs

75  
docs citations

75  
times ranked

5871  
citing authors

#	ARTICLE	IF	CITATIONS
1	Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 259-269.	5.1	58
2	Coronary vasomotor dysfunction in cancer survivors treated with thoracic irradiation. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 2976-2987.	1.4	7
3	Playing With Dynamite? A Cautious Assessment of TNT. <i>Journal of Clinical Oncology</i> , 2021, 39, 103-106.	0.8	21
4	A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 134-144.	0.4	61
5	Development and validation of a pancreatic cancer risk model for the general population using electronic health records: An observational study. <i>European Journal of Cancer</i> , 2021, 143, 19-30.	1.3	27
6	Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials. <i>JAMA Network Open</i> , 2021, 4, e213304.	2.8	4
7	Reply to A. Cercek et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 1186-1188.	0.8	0
8	Florid Foreign Body-type Giant Cell Response to Keratin Is Associated With Improved Overall Survival in Patients Receiving Preoperative Therapy for Esophageal Squamous Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, Publish Ahead of Print, 1648-1660.	2.1	1
9	Outcomes of trimodality CROSS regimen in older adults with locally advanced esophageal cancer. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2667-2674.	0.5	7
10	NGS-based identification and tracing of microsatellite instability from minute amounts DNA using inter-Alu-PCR. <i>Nucleic Acids Research</i> , 2021, 49, e24-e24.	6.5	12
11	Stereotactic Body Radiation Therapy to a Splenic Metastasis in Oligoprogressive Non-small Cell Lung Cancer. <i>Advances in Radiation Oncology</i> , 2020, 5, 516-521.	0.6	0
12	Contribution of FDG-PET/CT to the management of esophageal cancer patients at multidisciplinary tumor board conferences. <i>European Journal of Radiology Open</i> , 2020, 7, 100291.	0.7	5
13	High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy. <i>Oncologist</i> , 2019, 24, e275-e283.	1.9	18
14	Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response. <i>Annals of Nuclear Medicine</i> , 2018, 32, 165-174.	1.2	9
15	Pilot study on the impact of F18-labeled thymidine PET/CT on gross tumor volume identification and definition for pancreatic cancer. <i>Practical Radiation Oncology</i> , 2018, 8, 179-184.	1.1	3
16	Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 4027-4034.	0.7	21
17	Enhanced detection of microsatellite instability using pre-PCR elimination of wild-type DNA homo-polymers in tissue and liquid biopsies. <i>Nucleic Acids Research</i> , 2018, 46, e74-e74.	6.5	36
18	Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	82

#	ARTICLE	IF	CITATIONS
19	An International Collaborative Standardizing a Comprehensive Patient-Centered Outcomes Measurement Set for Colorectal Cancer. <i>JAMA Oncology</i> , 2017, 3, 686.	3.4	94
20	Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3214-3222.	3.2	44
21	Reply to S. Sorscher. <i>Journal of Clinical Oncology</i> , 2017, 35, 1746-1747.	0.8	0
22	Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 3671-3677.	0.8	112
23	Relationship between the Temporal Changes in Positron-Emission-Tomography-Imaging-Based Textural Features and Pathologic Response and Survival in Esophageal Cancer Patients. <i>Frontiers in Oncology</i> , 2016, 6, 72.	1.3	47
24	Persistence of dysphagia and odynophagia after mediastinal radiation and chemotherapy in patients with lung cancer or lymphoma. <i>Ecological Management and Restoration</i> , 2016, 30, 1-8.	0.2	1
25	Perils of the Pathologic Complete Response. <i>Journal of Clinical Oncology</i> , 2016, 34, 3959-3962.	0.8	35
26	Elimination of unaltered DNA in mixed clinical samples via nuclease-assisted minor-allele enrichment. <i>Nucleic Acids Research</i> , 2016, 44, gkw650.	6.5	55
27	Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 460-468.	0.8	363
28	Expert Consensus Contouring Guidelines for Intensity Modulated Radiation Therapy in Esophageal and Gastroesophageal Junction Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 911-920.	0.4	112
29	Enhanced Ratio of Signals Enables Digital Mutation Scanning for Rare Allele Detection. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 284-292.	1.2	26
30	Anorectal Cancer: Critical Anatomic and Staging Distinctions That Affect Use of Radiation Therapy. <i>Radiographics</i> , 2015, 35, 2090-2107.	1.4	42
31	Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma. <i>Oncologist</i> , 2014, 19, 637-638.	1.9	292
32	Reply to E.C. Smyth et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 3082-3082.	0.8	1
33	Bending the Cost Curve: A Unique Collaboration Between Radiation Oncologists and Blue Cross Blue Shield of Massachusetts to Optimize the Use of Advanced Technology. <i>Journal of Oncology Practice</i> , 2014, 10, e321-e327.	2.5	7
34	Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2014, 110, 160-164.	0.3	25
35	Supportive and palliative radiation oncology service: Impact of a dedicated service on palliative cancer care. <i>Practical Radiation Oncology</i> , 2014, 4, 247-253.	1.1	23
36	A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. <i>Practical Radiation Oncology</i> , 2014, 4, 316-322.	1.1	42

#	ARTICLE	IF	CITATIONS
37	Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. <i>Practical Radiation Oncology</i> , 2014, 4, e117-e123.	1.1	4
38	Combination Chemoradiation Therapy: The Whole Is More Than the Sum of the Parts. <i>Journal of Clinical Oncology</i> , 2014, 32, 367-369.	0.8	18
39	Upper abdominal normal organ contouring guidelines and atlas: A Radiation Therapy Oncology Group consensus. <i>Practical Radiation Oncology</i> , 2014, 4, 82-89.	1.1	103
40	A Phase I/II and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 830-838.	0.4	101
41	Gastric lymph node contouring atlas: A tool to aid in clinical target volume definition in 3-dimensional treatment planning for gastric cancer. <i>Practical Radiation Oncology</i> , 2013, 3, e11-e19.	1.1	23
42	Dosimetric predictors of nausea and vomiting: an exploratory analysis of a prospective phase I/II trial with neoadjuvant accelerated short-course radiotherapy and capecitabine for resectable pancreatic cancer. <i>Journal of Radiation Oncology</i> , 2013, 2, 427-434.	0.7	5
43	Differential strand separation at critical temperature: A minimally disruptive enrichment method for low-abundance unknown DNA mutations. <i>Nucleic Acids Research</i> , 2013, 41, e50-e50.	6.5	22
44	Prognostic markers of time to local recurrence and overall survival in early-stage rectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 473-473.	0.8	0
45	The impact of positive margins on outcome among patients with gastric cancer treated with radiation.. <i>Journal of Clinical Oncology</i> , 2013, 31, 81-81.	0.8	0
46	Prevalence and significance of subcentimeter hepatic lesions in patients with localized pancreatic adenocarcinoma. <i>Practical Radiation Oncology</i> , 2012, 2, e89-e94.	1.1	5
47	Temperature-Tolerant COLD-PCR Reduces Temperature Stringency and Enables Robust Mutation Enrichment. <i>Clinical Chemistry</i> , 2012, 58, 1130-1138.	1.5	32
48	Immediate versus delayed adjuvant chemoradiation for resected pancreatic cancer: An analysis of local control and survival.. <i>Journal of Clinical Oncology</i> , 2012, 30, 301-301.	0.8	0
49	Phase I/II study of preoperative (pre-op) short course chemoradiation (CRT) with proton beam therapy (PBT) and capecitabine (cape) followed by early surgery for resectable pancreatic ductal adenocarcinoma (PDAC) of the head.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4021-4021.	0.8	1
50	Multiplex Amplification Coupled with COLD-PCR and High Resolution Melting Enables Identification of Low-Abundance Mutations in Cancer Samples with Low DNA Content. <i>Journal of Molecular Diagnostics</i> , 2011, 13, 220-232.	1.2	31
51	A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma. <i>Cancer</i> , 2011, 117, 2620-2628.	2.0	24
52	Phase I Study of Preoperative Short-Course Chemoradiation With Proton Beam Therapy and Capecitabine for Resectable Pancreatic Ductal Adenocarcinoma of the Head. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 151-157.	0.4	67
53	Automatic marker detection and 3D position reconstruction using cine EPID images for SBRT verification. <i>Medical Physics</i> , 2009, 36, 4536-4546.	1.6	40
54	Impact of Manual and Automated Interpretation of Fused PET/CT Data on Esophageal Target Definitions in Radiation Planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1612-1618.	0.4	30

#	ARTICLE	IF	CITATIONS
55	Infrared-Guided Patient Setup for Lung Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1124-1133.	0.4	10
56	Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. <i>Nature Medicine</i> , 2008, 14, 579-584.	15.2	346
57	Sign of Leser-Trélat in Newly Diagnosed Advanced Gastric Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 4992-4993.	0.8	9
58	Preferential Amplification of Apoptotic DNA from Plasma: Potential for Enhancing Detection of Minor DNA Alterations in Circulating DNA. <i>Clinical Chemistry</i> , 2008, 54, 1582-1584.	1.5	12
59	A novel method for estimating SBRT delivered dose with beam's-eye-view images. <i>Medical Physics</i> , 2008, 35, 3225-3231.	1.6	22
60	FDG-PET/CT Tumor Segmentation-Derived Indices of Metabolic Activity to Assess Response to Neoadjuvant Therapy and Progression-Free Survival in Esophageal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 377-388.	0.6	82
61	DNA Degradation Test Predicts Success in Whole-Genome Amplification from Diverse Clinical Samples. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 441-451.	1.2	56
62	Shielding of the Hip Prosthesis During Radiation Therapy for Heterotopic Ossification is Associated with Increased Failure of Prophylaxis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1499-1505.	0.4	10
63	Dosimetric Feasibility of Hypofractionated Proton Radiotherapy for Neoadjuvant Pancreatic Cancer Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1557-1566.	0.4	51
64	Clinical Feasibility of Using an EPID in cine Mode for Image-Guided Verification of Stereotactic Body Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 258-266.	0.4	67
65	Considerations in Treatment Planning for Esophageal Cancer. <i>Seminars in Radiation Oncology</i> , 2007, 17, 53-61.	1.0	26
66	Is radiation therapy required for patients with intermediate-risk rectal cancer?. <i>Clinical Advances in Hematology and Oncology</i> , 2007, 5, 638-44, 585.	0.3	0
67	Whole Genome Amplification of Plasma-Circulating DNA Enables Expanded Screening for Allelic Imbalance in Plasma. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 22-30.	1.2	33
68	Heterotopic ossification: Pathophysiology, clinical features, and the role of radiotherapy for prophylaxis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1289-1299.	0.4	259
69	In reply to Dr. Luh et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1598.	0.4	1
70	Antiprimer Quenching-Based Real-Time PCR and Its Application to the Analysis of Clinical Cancer Samples. <i>Clinical Chemistry</i> , 2006, 52, 624-633.	1.5	32
71	Treatment planning for resected abdominal tumors: Differences in organ position between diagnostic and radiation-planning computed tomography scans. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1613-1620.	0.4	11
72	High Risk of Brain Metastases in Surgically Staged IIIA Non-Small-Cell Lung Cancer Patients Treated With Surgery, Chemotherapy, and Radiation. <i>Journal of Clinical Oncology</i> , 2005, 23, 1530-1537.	0.8	168

#	ARTICLE	IF	CITATIONS
73	Perioperative radiotherapy for cancer of the esophagus. <i>Journal of Surgical Oncology</i> , 2001, 20, 33-39.	1.4	2
74	Allergic Skin Reactions to Anticonvulsant Medications in Patients Receiving Cranial Radiation Therapy. <i>Epilepsia</i> , 1999, 40, 341-344.	2.6	66
75	Raf-1: A kinase currently without a cause but not lacking in effects. <i>Cell</i> , 1991, 64, 479-482.	13.5	162